Gilead Sciences, Inc.

Novartis Vaccines & Diagnostics, Gmbh

Shaopei Cai

Gary Bruce Phillips

Musong Kim

Joshua A Kaplan

Kirk L Stevens

Marcin Stasiak

Jennifer Alissa Loyer-Drew

William Baker

Lafe J Purvis, Ii

Josh Van Veldhuizen

William John Watkins

Barton W Phillips

Devan Naduthambi

Zhimin Du

Suet Chung Yeung

Jennifer Anne Treiberg

Augustus O Okhamafe

Joshua J Van Veldhuizen

Leena Patel

Stephane Perreault

Timothy D Machajewski

David M Ryckman

Marion Wiesmann

Eric Harwood

Carla C Heise

Shuguang Zhu

Xiao Shang

Joyce Chou

Kirk K Stevens

William J Watxins

David Ryckman

Marc S Tesconi

The present application provides the compounds of formula (J), or pharmaceutically acceptable salts, isomers, tautomer, or a mixture thereof, wherein n, W, A', B&#x2032;, R, R, and Rare described herein. The compounds are inhibitors to the activities of phosphatidylinositol 3-kinase (PI3K) and are useful for treating conditions mediated by one or more PI3K isoforms. The present application further provides pharmaceutical compositions that include a compound of formula (I), or pharmaceutically acceptable salts, isomers, tautomer, or mixture thereof, and methods of using these compounds and compositions for treating conditions mediated by one or more PI3K isoforms.

Phosphatidylinositol 3-kinase inhibitors

The present application provides the compounds of formula (J), or pharmaceutically acceptable salts, isomers, tautomer, or a mixture thereof, wherein W, B, n, m, A', R, R, and Rare described herein. The compounds are inhibitors to the activities of phosphatidylinositol 3-kinase (PI3K) and are useful for treating conditions mediated by one or more PI3K isoforms. The present application further provides pharmaceutical compositions that include a compound of formula (I), or pharmaceutically acceptable salts, isomers, tautomer, or mixture thereof, and methods of using these compounds and compositions for treating conditions mediated by one or more PI3K isoforms.

This invention provides compounds of the formula:  wherein Rand Rtogether with the phenyl to which they are bound may form a bicyclic, fused heterocyclic ring and all other variables are as defined herein, their use in pulmonary inflammation or bronchoconstriction therapy and compositions comprising and processes for preparing the same are provided.

Bi-functional pyrazolopyridine compounds

Provided are compounds of Formula I:  Rand Rtogether with the phenyl to which they are bound may form a bicyclic, fused heterocyclic ring, and all other variables are as defined herein, as well as their use in treating pulmonary inflammation or bronchoconstriction and compositions comprising and processes for preparing the same.

Bi-functional quinoline analogs

Methods of inhibiting fibroblast growth factor receptor 3 and treating various conditions mediated by fibroblast growth factor receptor 3 are provided that include administering to a subject a compound of Structure I, a pharmaceutically acceptable salt thereof, a tautomer thereof, or a pharmaceutically acceptable salt of the tautomer. Compounds having the Structure I have the following structure where and have the variables described herein. Such compounds may be used to prepare medicaments for use in inhibiting fibroblast growth factor receptor 3 and for use in treating conditions mediated by fibroblast growth factor receptor 3 such as multiple myeloma. 

Inhibition of FGFR3 and treatment of multiple myeloma

Growing community of inventors

Seattle, WA, United States of America

Shaopei Cai